Fig. 2From: CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapyDisease-free survival curve (a) and disease-specific survival curve (b) of groups with and without CAIX expression. In the curves, DFS and DSS were higher in patients with tumors that expressed CAIX than in those who did not express CAIX (log-rank, p = 0.005 and p = 0.012, respectively)Back to article page